利妥昔单抗治疗皮肤淋巴增生症3例报告

Dermatology case reports Pub Date : 2019-03-22 DOI:10.35248/2684-124X.19.4.150

M. Matin, A. Asilian, Samaneh Mozafar Poor, Elaheh Haftbaradaran, A. Feily

{"title":"利妥昔单抗治疗皮肤淋巴增生症3例报告","authors":"M. Matin, A. Asilian, Samaneh Mozafar Poor, Elaheh Haftbaradaran, A. Feily","doi":"10.35248/2684-124X.19.4.150","DOIUrl":null,"url":null,"abstract":"Benign Cutaneous Lymphoid Hyperplasia (CLH) is a B-cell pseudolymphoma of an unknown origin. The face is the most affected site in CLH. This report presents the cases of 3 patients with CLH who were treated with rituximab. \n \nIt is a hypothesis that rituximab is useful for treating resistant-to-relapsing forms of CLH that do not respond to previous therapies but must be checked with appropriate designs research.","PeriodicalId":92997,"journal":{"name":"Dermatology case reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Treatment of Cutaneous Lymphoid Hyperplasia with Rituximab: A Case Report of 3 Patients\",\"authors\":\"M. Matin, A. Asilian, Samaneh Mozafar Poor, Elaheh Haftbaradaran, A. Feily\",\"doi\":\"10.35248/2684-124X.19.4.150\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Benign Cutaneous Lymphoid Hyperplasia (CLH) is a B-cell pseudolymphoma of an unknown origin. The face is the most affected site in CLH. This report presents the cases of 3 patients with CLH who were treated with rituximab. \\n \\nIt is a hypothesis that rituximab is useful for treating resistant-to-relapsing forms of CLH that do not respond to previous therapies but must be checked with appropriate designs research.\",\"PeriodicalId\":92997,\"journal\":{\"name\":\"Dermatology case reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2684-124X.19.4.150\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2684-124X.19.4.150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

良性皮肤淋巴样增生(CLH)是一种来源不明的b细胞假性淋巴瘤。面部是CLH中受影响最大的部位。本文报告了3例接受利妥昔单抗治疗的CLH患者。这是一种假设，即利妥昔单抗可用于治疗对先前治疗无效的抗复发型CLH，但必须通过适当的设计研究进行验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Treatment of Cutaneous Lymphoid Hyperplasia with Rituximab: A Case Report of 3 Patients

Benign Cutaneous Lymphoid Hyperplasia (CLH) is a B-cell pseudolymphoma of an unknown origin. The face is the most affected site in CLH. This report presents the cases of 3 patients with CLH who were treated with rituximab. It is a hypothesis that rituximab is useful for treating resistant-to-relapsing forms of CLH that do not respond to previous therapies but must be checked with appropriate designs research.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Dermatology case reports

自引率

0.00%

发文量